Pembrolizumab/Vibostolimab Co-Formulation for Oral Squamous Cell Carcinoma
This trial is testing a new cancer drug, given alone or with other anticancer therapies, to see if it is safe and effective in treating people with advanced solid tumors.
- Oral Squamous Cell Carcinoma
- Endometrial Cancer
- Breast Cancer
- Gallbladder Cancer
- Cervical Cancer
- Squamous Cell Carcinoma
- Liver Cancer
- Bladder Cancer
- Ovarian Tumors
- Bile Duct Cancer
- Esophageal Cancer
- Stomach Tumors
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Has the Pembrolizumab/Vibostolimab Co-Formulation been granted authorization by the FDA?
"Although clinical data demonstrates pembrolizumab/vibostolimab co-formulation is safe, it has not yet been tested for efficacy. Thus, our team at Power rated its safety a 2 on the 1 to 3 scale."
How many centers are managing this trial?
"This clinical trial is being held at 15 sites, including Houston Methodist Hospital (Site 1017) in Texas, Alaska Womens Cancer Care ( Site 1016) in Anchorage, and Memorial Sloan Kettering-Commack (Site 1021) in New York."
Are individuals currently able to apply for this trial?
"Clinicaltrials.gov records show that this research endeavour remains open to volunteer enrolment, having been first posted on the 16th of September 2021 and last edited on November 25th 2022."
To what extent is the Pembrolizumab/Vibostolimab Co-Formulation employed as a medical treatment?
"Pembrolizumab/Vibostolimab Co-Formulation is the preferred medication for treating malignant neoplasms. Moreover, this dual formulation has also demonstrated efficacy in patients suffering from unresectable melanoma, microsatellite instability high, and rectal carcinoma."
To what extent has Pembrolizumab/Vibostolimab Co-Formulation been tested in previous clinical research trials?
"Since 1997, the City of Hope Comprehensive Cancer Center has conducted 3694 clinical trials involving Pembrolizumab/Vibostolimab Co-Formulation. At present, 2429 ongoing studies are occurring in various cities around the world; Houston being one such location."
What is the scope of subjects within this medical experiment?
"To adequately perform this trial, MSD Corp. requires 610 qualified patients; locations of enrolment include Houston Methodist Hospital (Site 1017) and Alaska Womens Cancer Care ( Site 1016)."
With what aims has this experiment been designed?
"The primary purpose of this trial is to evaluate Progression-Free Survival (PFS) per RECIST 1.1 as Assessed by BICR over the course of two years. To gauge success, researchers will also assess Duration of Response (DOR), defined as time from confirmed CR or PR until PD or death according to RECIST 1.1 criteria, and Objective Response Rate (ORR). All measurements are evaluated with the aid of an investigator following RECIST standards."